What it is
Systemic estrogen therapy means estrogen that circulates through the whole body. Because it travels through the bloodstream, it can address symptoms that involve many body systems at once. Women who still have a uterus and use systemic estrogen also typically take a progestogen, which protects the uterine lining.
Common forms
Patches, gels, and sprays deliver estrogen through the skin (transdermal); pills deliver it through the digestive system (oral). These routes are processed differently by the body, and the differences — including how each route relates to blood clot risk — are a common and worthwhile topic to raise at a visit.
When it comes up
Systemic estrogen is the treatment most often discussed for moderate to severe vasomotor symptoms — hot flashes and night sweats — and it is also discussed in the context of preventing bone loss. Women whose sleep, mood, or daily functioning are significantly affected by vasomotor symptoms often find this is the first option their clinician raises.
Common misconceptions
Many women arrive believing hormone therapy was “proven dangerous.” That impression traces largely to early reporting on the Women's Health Initiative study in 2002, which has since been extensively reanalyzed. Our understanding of menopausal hormone therapy has evolved substantially over the past two decades; today, discussions are individualized based on a woman's age, symptoms, time since menopause, and personal medical history — which is exactly why this is a conversation, not a yes/no fact.
What women often notice
Not guaranteed, and not everyone — educational only. Women using systemic estrogen for vasomotor symptoms often report improvements in hot flashes, night sweats, sleep, and overall quality of life. Some notice changes within weeks, while others improve more gradually; follow-up visits are where expectations and progress are reviewed.
Questions you may wish to discuss
- Given my age and health history, how do the benefits and risks balance for me?
- What's the difference between transdermal and oral estrogen in my situation?
- If I still have a uterus, what progestogen options exist?
- How long before I might notice improvement, and how is treatment reviewed over time?
✓ EVIDENCE SNAPSHOT
The Menopause Society's position is that for most healthy women under 60, or within 10 years of their final menstrual period, who have bothersome vasomotor symptoms, the benefits of hormone therapy generally outweigh the risks — and that decisions should be individualized based on personal health history.¹,²
Learn next
- Vasomotor symptoms
- Transdermal vs. oral estrogen
- Progesterone
- Bone health
- Sleep
- The North American Menopause Society (now The Menopause Society). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767–794.
- Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. 2017;318(10):927–938.
- The North American Menopause Society (now The Menopause Society). The 2020 Genitourinary Syndrome of Menopause Position Statement of The North American Menopause Society. Menopause. 2020;27(9):976–992.
- The North American Menopause Society (now The Menopause Society). The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society. Menopause. 2023;30(6):573–590.
- Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660–4666.
- Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
- American College of Obstetricians and Gynecologists. Practice Bulletin No. 141: Management of Menopausal Symptoms. Obstet Gynecol. 2014;123(1):202–216.